Process Development

Viral Vector

Accelerating viral vector development and scale-up. Our expertise ensures high-yield, high-purity AAV and lentivirus production.

Optimising Viral Vector Manufacturing

Viral vector manufacturing faces yield, purity, and scalability challenges that can hinder clinical progression and commercial viability. Optimising upstream and downstream processes is essential for efficient production and regulatory compliance.

We develop customised, phase-appropriate vector processes, with expertise in AAV and lentivirus platforms. We optimise transfection, cell culture conditions, purification, and formulation, ensuring vectors meet quality, potency, and cost-of-goods (CoG) targets.

Our Processes

We leverage advanced process development strategies, including:

Suspension and adherent vector production

Scaling from 250 mL to 200 L bioreactors using the Ambr250 Modular and Eppendorf BioFlo / BioBLU c platforms.

Comprehensive AAV and Lentivirus Expertise

With experience across multiple AAV serotypes (2, 3, 5, 6, 8, 9, 10 + proprietary variants).

AAV Platform Process

Available with customisation options based on data-driven and cost-of-goods (CoG) considerations. We offer a non-proprietary platform that belongs entirely to our clients.

Chromatography-based purification and enrichment

Using Cytiva AKTA platforms (Avant x2, Pure, and Pilot) for optimisation screening, DoE studies, and large-scale bulk purification.

Custom process optimisation

Including screening studies, stability studies, process robustness, and material generation.

Integrated Cell Banking Capabilities

Including controlled rate freezing.

Direct access to translation consultants, CMC experts, and QPs

Ensuring regulatory foresight and informed process development decisions.

Key People

Daphné Bocciarelli

Head of Vector

Clare Blue

Senior CMC Translation Consultant

David Vincent

Head of Process Development

Why Partner with Us?

Advanced Scale-Up Expertise

Extensive experience in scaling AAV and lentivirus production, optimising bioreactor performance and downstream purification.

Regulatory-Driven Process Design

Early integration of regulatory requirements to streamline clinical and commercial approvals.

Customisable Platform Technologies

Offering both standardised and bespoke development strategies, ensuring flexibility in process optimisation.

Seamless Technology Transfer

Supporting the transition to GMP manufacturing, reducing risk and improving process consistency.

Optimise Your Viral Vector Process with eXmoor Pharma

From proof-of-concept studies to full-scale GMP production, we develop efficient, high-yield viral vector processes. Contact us today to discuss how we can support your viral vector development.

Request a Proposal

Other Process Development Services

Cell Therapy

Our cell therapy process development team supports both autologous and allogeneic therapies, ensuring robust, scalable, and regulatory-ready processes. We have experience in iPSCs, MSCs, and immune cells, with expertise across 2D and 3D culture systems, bioreactor-based expansion, and cryopreservation strategies. Our team helps clients transition from lab-scale research to GMP manufacturing, ensuring process consistency and quality at every stage.

RNA

RNA-based therapies, including mRNA, saRNA, and cRNA, require highly controlled, reproducible processes. Our expertise covers in vitro transcription (IVT), purification, lipid nanoparticle (LNP) encapsulation, and fill-finish. We offer a phase-appropriate development platform, enabling rapid process optimisation while ensuring smooth transition to GMP manufacturing.